Teoxane Approach to periorbital

THE TEOXANE APPROACH

In aesthetics medicine, most patients expect to obtain natural-looking and balanced outcomes.7 Working with your expertise, the TEOXANE approach allows you to tailor your technique to optimal, natural-looking and unique results for your patients, maintaining the dynamic movement of the face (the 4th facial dimension).

 

Right products at the right places with the right techniques.

THE TEOXANE APPROACH TO PERIORBITAL
References

1.Teoxane internal data source. Teosyal Redensity 2 deliveries from 2012 to 2020: 1'011'774 boxes

2.Berguiga et al. Orbit, 2017; 36(1):22-26.

3.TEOSYAL ® PURESENSE REDENSITY 2 – instruction for use

4.TEOXANE R&D report RDRE 2023. Data on File. Physical analysis of HA fillers intended for infraborbital uses. Torsion and compression tests assessed on a rheometer. The measurement of the rheological parameter Delta index represents the balance between gel viscosity and elasticity. . 

5.TEOSYAL RHA® 4 – instruction for use

6.RDRE 2015 - Rheological analysis of Volumizers _ Ultra Deep_RHA4_Lyft_Voluma

7. Michaud et al. J Cosmet Dermatol. 2015; 14(1): 9–21

8. Arcane Research Study conducted in France in March 2018 on 8.646 women from 18 to 75 y/o

9. Teoxane data source TEO-RHA-1902 Injection Guidelines

10. Funt. J Clin Aesthet Dermatol. 2011; 4(12):32-63

11. Bravo et al. J Clin Aesthet Dermatol. 2015; 8(6):30-5

12. Glaser et al. Dermatol Surg 2018; 44:1547-1554

13. Beleznay et al. Dermatol Surg. 2015; 41:1097-1117

14. Teoxane Post Market Surveillance data November 2020. 1445 practitioners worldwide

15. Ramanadham et al. Plast Reconstr Surg. 2015; 136:49S-55S

16.Teoxane Worldwide Survey "Periorbital Treatments in Clinics" by 180 injectors, June 2020

17. Cotofana et al. Facial Plast Surg. 2016; 32:253-260

18. Lemaire. E2e Medical Publishing, Master Collection 2, Paris, 2011

19. Kaufman-Janette et al. J Cosmet Dermatol. 2019; doi: 10.1111/jocd.1310

20. Rzany et al. Dermatol Surg; 2019; 45(10):1304-1314

21. TEOXANE Post-Marketing Surveillance from 2016 to 2020-Q3

22. Data on file 2020. Syneos study report 7010664.SA.259

23. Sharad. J Cutan Aesthet Surg. 2012; 5:229238

24. Sadick et al. Cosmet Dermatol. 2007;6(4):218-22

25. The properties of ingredients derive from data communicated by the raw material manufacturers

26.Efficacy study. Results measured after 28 days of use

 

 

* REDENSITY 2 = TEOSYAL® PureSense REDENSITY 2

# Depending on the country registration, TEOSYAL RHA® 4 exists in 1 mL

Find a practitioner

Required fields*

I agree to receive exclusive offers and the latest news from Hyaluronic-acid.com
Choose your country

Close

close
Europe

France

UK

Germany

Italy

Poland

Switzerland

Spain

Russia

International

English

French

Asia Pacific

Australia

Come back to consumer area

You are switching to our professional universe

close